Update: First patients dosed with COVID-19 nanovaccine in Phase 1 trial
Moderna (MA, USA) has developed a mRNA vaccine – mRNA-1273 – for use against SARS-CoV-2, which is currently undergoing clinical trials in the USA.
The vaccine is made up of mRNAs encoding antigenic viral full-length S, S1 or S2 proteins from SARS-CoV and MERS-CoV virus strains and encapsulated in cationic lipid nanoparticles for more efficient delivery.
Now, Moderna has announced that the first patients have been dosed with the vaccine as part of the Phase 1 trial.
See the timeline of the vaccine’s development here: Timeline of response from Moderna.
For the full story head over to our sister site, Infectious Disease Hub.
For access to more articles please register to The Nanomed Zone for free!
Submit Your Research to the F1000Research Nanoscience Gateway
Drive innovation in nanomedicine by sharing your research through the F1000Research Nanoscience Gateway. With trusted publishing, open access, and transparent peer review, your work will meet the highest standards of rigor and integrity while advancing the understanding and application of nanotechnology in medicine.
Join a platform that prioritizes transparency, openness, and author control. Submit your research today at F1000Research Nanoscience Gateway.
